C. difficile spores are highly resistant to desiccation, chemicals and extreme temperature. Spores frequently contaminate the environment around patients with CDI, potentially persisting for ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

When those bacteria die — for instance, as a result of antibiotic treatment for an unrelated infection — the large intestine ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

There are about 500,000 cases of C. difficile each year; about one in six people with the infection will see it come back within two to eight weeks of the initial infection. “Treatment of C.

The bacterial infection is easily passed from person to person. It is thought to affect around one-third of the U.S.

In the period spanning 2017-2021, a mere 12 new antibiotics entered the market, with only one capable of targeting all the ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Therefore, a two-step diagnostic algorithm with a rapid highly sensitive screening method to identify positive samples, to be confirmed by gold standard, should be strongly recommended. Some ...